NBIX NEUROCRINE BIOSCIENCES INC Insider Trading

NBIX CLO Darin Lippoldt sold 10,000 shares at $179.60 on 2026-07-09 via 10b5-1 plan; retains 54,729 shares plus 4,965 options.

Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences, sold 10,000 shares (10.0K shares) for $1,796,014.00 on 2026-07-09 as part of a pre-arranged 10b5-1 trading plan adopted on 2025-06-09—a scheduled transaction unrelated to discretionary timing decisions. Post-transaction, Lippoldt holds 54,729 shares in non-derivative form plus 4,965 shares in non-qualified stock options, representing a partial reduction of -15.4% from his pre-transaction holdings but not an exit of his overall position. The stock currently trades at $174.10, down 3.9% from its 52-week high of $181.18; this sale occurred 10 days prior to the current quote, near the upper end of the annual range. Looking at Lippoldt's prior NBIX-specific transactions, measurable outcomes from his December 2025 and July 2024 sales showed negative 90-day returns (-19.7% and -22.4% respectively), though three recent June 2026 sales lack outcome data yet. His cross-ticker track record shows 8 prior sells with an average 90-day return of -3.3%, indicating a pattern of sales that have historically been followed by modest declines.

Ingrid Delaet (Chief Regulatory Officer) sold 14,571 shares over 3 days for $2,603,112.00 under pre-arranged 10b5-1 plan; retains 16,225 shares plus 42,037 in options

Ingrid Delaet, Chief Regulatory Officer at Neurocrine Biosciences (NBIX), executed three scheduled sales totaling 14,571 shares for $2,603,112.00 at a blended average price of $178.65. This reduction represents a 47.3% decrease from her pre-transaction holdings of 30,796 shares, conducted under a 10b5-1 trading plan adopted on 2026-02-27, meaning the sale was pre-arranged rather than discretionary. Her post-transaction holdings of 16,225 non-derivative shares, coupled with 42,037 remaining shares in non-qualified stock options across three tranches, indicate her overall position in the company remains substantial. The stock has appreciated 9.3% over the prior 30 days and 40.1% over 90 days, trading near its 52-week high of $181.00 at a current price of $180.55, while the company's fundamentals show strong recent performance with $814.5M in latest quarterly revenue, $197.9M net income, and 21.4% annual revenue growth. The structured, calendar-based nature of this transaction removes timing inference and positions it as standard equity plan execution rather than a discretionary signal.

CLO Darin Lippoldt sells 10,000 shares at $170.15 avg under 10b5-1 plan; retains 54.7K shares plus derivative holdings.

Chief Legal Officer Darin Lippoldt executed 3 separate sales totaling 10,000 shares for $1,701,492.09 through a pre-arranged 10b5-1 trading plan adopted 2025-06-09, reducing his non-derivative holdings from 64.7K to 54.7K shares. The sales occurred at $170.15 blended average price against a current price of $168.54, with the broader context showing stock up +27.1% over 90 days and +6.5% over 30 days. Lippoldt retains 54.7K non-derivative shares plus 56,385 shares in derivative form (3 tranches of non-qualified stock options), indicating no overall portfolio exit. His prior same-ticker sell history at NBIX shows mixed timing outcomes: the most recent 2025-12-08 sale declined -11.9% at 30 days and -19.7% at 90 days, while earlier 2023 sales captured gains in both 30- and 90-day forward windows. The scheduled nature of this transaction under a 10b5-1 plan, combined with the insider's substantial remaining exposure to NBIX equity, limits inference about conviction or market view.

Director Stephen A Sherwin sold 25,000 NBIX shares for $4.1M via 5 separate transactions on 2026-06-05 under 10b5-1 plan

Stephen A Sherwin, a director at Neurocrine Biosciences, executed 5 separate sales totaling 25,000 shares for $4,132,968.87 at prices ranging from $163.81 to $167.31 on 2026-06-05, reducing his non-derivative holdings from 40,860 shares to 15,860 shares (-61.2%). This transaction was scheduled under a pre-arranged 10b5-1 trading plan adopted on 2026-03-06, meaning it was not discretionary. At the time of the sales, the current stock price of $165.24 was near the blended average transaction price of $165.32 and within 2.6% of the 52-week high of $169.57. The company's fundamentals remain solid with $814.5M in latest quarterly revenue, $197.9M net income, and 21.4% annual revenue growth, though the P/E of 24.85 reflects current market valuation. No derivative securities remain after this filing.

NBIX CHRO Julie Cooke sells 36,937 shares across 5 transactions for $5,770,235.26 under 10b5-1 plan

Julie Cooke, Chief Human Resources Officer at Neurocrine Biosciences, executed 5 separate sales on 2026-06-02 totaling 36,937 shares for $5,770,235.26 at a blended average price of $156.22, reducing her non-derivative holdings to 22,374 shares. This sale was conducted under a pre-arranged 10b5-1 trading plan adopted on 2026-03-03, meaning the timing and execution were scheduled rather than discretionary. Notably, Cooke's same-ticker history at NBIX shows mixed outcomes on her prior 4 sales at this company, with results ranging from -18.9% to +1.0% over 90 days where measurable. The stock currently trades at $167.35, reflecting a 30-day appreciation of 23.9% and 90-day gain of 30.6%, positioned near its 52-week high of $165.81.

CSO Jude Onyia sold 11,000 NBIX shares at $160.25 (scheduled 10b5-1 plan, retains 13,268 options)

Chief Scientific Officer Jude Onyia sold 11,000 shares at $160.25 on 2026-06-01, reducing non-derivative holdings by 29.9% from 36,846 to 25,846 shares, with a total transaction value of $1,762,710.40. This sale is part of a pre-arranged 10b5-1 trading plan adopted on 2026-02-25, meaning the transaction was scheduled rather than discretionary. The stock's current price of $154.84 sits 4.6% below its 52-week high of $162.39, and the company reports strong fundamentals with net income of $197,900,000.00 on revenue of $814,500,000.00 and annual revenue growth of +21.4%. The insider retains 13,268 non-qualified stock options, maintaining a material position in the company. His prior two sales at NBIX showed mixed outcomes: a -4.2% 30-day return and a -0.9% 30-day return, though 90-day returns were positive at +5.0% and +7.9% respectively.

NBIX Chief Scientific Officer Jude Onyia sells 11,000 shares at $155.53 via pre-arranged 10b5-1 plan; retains 25,846 shares plus 24,268 options.

Jude Onyia, Chief Scientific Officer, executed a scheduled sale of 11,000 shares for $1,710,865.20 under a pre-arranged 10b5-1 trading plan adopted on 2026-02-25, reducing non-derivative holdings by 29.9% from 36,846 to 25,846 shares while retaining 24,268 non-qualified stock options. The sale occurred at $155.53, which is 2.5% below the 52-week high of $162.39, as the stock has risen 20.6% over the past 30 days and 19.7% over 90 days. His prior two sales at NBIX showed mixed outcomes: the 2025-07-09 sale saw 30-day returns of -4.2% but 90-day returns of +5.0%, while the 2025-07-02 sale had 30-day returns of -0.9% and 90-day returns of +7.9%. Because this sale is scheduled rather than discretionary, price timing cannot be inferred as a signal of insider conviction. With NBIX fundamentals showing $814.5M in latest quarterly revenue, $197.9M net income, and 21.4% annual revenue growth, the transaction reflects a routine vest-and-sell within a pre-approved framework.

Director Kevin Charles Gorman sold 245,088 shares of NBIX at $154.33 for $37.8M under 10b5-1 plan; retains 511,293 shares.

Director Kevin Charles Gorman executed a scheduled sale of 245,088 shares at $154.33 on 2026-05-19 under a pre-arranged 10b5-1 trading plan adopted on 2026-02-17, reducing his holdings to 511,293 shares from 756,381 shares. His prior five trades at NBIX show mixed near-term outcomes: three measurable sales posted 30-day returns of +14.0%, +5.3%, and -21.3%, while his cross-ticker track record across all tickers shows 8 prior sells with an average 90-day return of +1.4%. NBIX fundamentals remain solid with annual revenue growth of +21.4%, net income of $197,900,000.00, and a P/E of 23.38, though the stock currently trades at $155.50, down -4.2% from the 52-week high of $162.39. This is a scheduled, non-discretionary transaction, so timing characterization is not applicable.

Director Richard Pops sold 15,000 NBIX shares at $157.65 for $2.4M via pre-arranged 10b5-1 plan on 2026-05-15.

Richard F Pops sold 15,000 shares (30.3% of his pre-transaction holdings of 49.5K shares) at $157.65, leaving him with 34.5K shares post-transaction. This sale was executed under a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. The company's fundamentals remain solid with revenue of $814.5M (annual growth +21.4%) and net income of $197.9M, supporting a current valuation of $15.8B market cap at a P/E of 23.64. The stock has appreciated 18.0% over the past 30 days and 23.0% over 90 days, trading at $157.21 currently, near its 52-week high of $162.39. As a scheduled transaction under a 10b5-1 plan, this sale carries no timing signal and should be evaluated solely as a change in the director's residual position from 49.5K to 34.5K shares.

CEO Gano Kyle sold 36,400 shares at $132.70–$132.71 on 2026-01-16 under pre-arranged 10b5-1 plan; retains 140,407 shares.

Gano Kyle executed 2 separate sales totaling 36,400 shares for $4,830,458.10 under a 10b5-1 trading plan adopted on 2025-05-20. The pre-arranged nature of this transaction means the timing and execution reflect a scheduled strategy rather than a discretionary decision. Post-transaction, Kyle retains 140,407 shares, representing a 20.6% reduction in his pre-transaction holdings of 176,807 shares. This level of ongoing ownership retention suggests continued material economic interest in the company.